CryoPort Inc. Common Stock (CYRX)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses whose earning power is durable and whose price offers a margin of safety. CryoPort provides temperature-controlled supply chain solutions for biopharma, animal health, and reproductive medicine, so the service is specialized. But the numbers show a business still searching for steady profitability. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $49.0M and net income was -$8.3M, with diluted EPS of -$0.20. That followed a fiscal Q1 2026 net loss of $10.5M, or -$0.25 per diluted share, and a fiscal Q2 2025 profit of $108.9M, or $2.13 per diluted share. The swing is enormous, which tells me reported earnings are not yet a reliable measure of earning power. For fiscal year 2025, revenue was $176.2M and net income was $78.3M; for fiscal year 2024, revenue was $156.8M and net loss was $114.8M. Growth exists, but profitability is inconsistent. Financial health is mixed. FairStock's debt-to-equity of 0.47 is not alarming, but its Altman Z-Score of 1.03 and Piotroski F-Score of 5/9 suggest fragility. Trailing free cash flow is -$21.3M and FCF yield is -2.5%, so the company is consuming cash. At the 2026-10-13 close of $16.95, FairStock calculates a negative P/E of -20.67, P/B of 1.93, ROE of -6.54%, and ROCE of -2.39%. FairStock's Lynch category is TURNAROUND, based on a return to profit after earlier losses, but the recent quarters moved back into losses. The market cap is $858.5M. I see a specialized operation with growth, but no clear margin of safety until free cash flow and net income turn consistently positive. At this price, it looks speculative rather than a classic value bargain.

In plain English: CryoPort helps move and store very cold biological materials for medical and research customers. The business is growing sales, but it has swung between big profits and losses and is losing money again in recent quarters. At the recent stock price, the shares look neither clearly cheap nor clearly expensive based on the company's uneven earnings and book value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer